Abstract: The embodiments disclosed herein provide compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, wherein R1 to R7 are as defined in the description. This application also provides a preparation method and a medical use of the compounds. The compounds of this disclosure have an activity superior or equivalent to the candidate drug LY2835219 currently under phase III clinical trial, and some of the compounds exhibit better selectivity. Moreover, the preferred compounds exhibit good absorption and good blood-brain distribution when administered orally.

Abstract: N-polar transistor structures have relied on the use of dry etch processes that use plasmas generated from gaseous species to remove III-N layers as commercially viable wet etchants do not exist. The present disclosure reports on methods for the fabrication of N-polar III-N transistors using wet etches along with transistor structures that are enabled by the availability of wet-etches.

Abstract: The embodiments disclosed herein provide compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, wherein R1 to R7 are as defined in the description. This application also provides a preparation method and a medical use of the compounds. The compounds of this disclosure have an activity superior or equivalent to the candidate drug LY2835219 currently under phase III clinical trial, and some of the compounds exhibit better selectivity. Moreover, the preferred compounds exhibit good absorption and good blood-brain distribution when administered orally.

Abstract: A method for controlling gear shifting, including: acquiring a current gear-shifting parameter of the vehicle (101); according to the current gear-shifting parameter and a preset target rotational speed, determining a gear-shifting inputted rotational speed (102); and when a rotational speed of the vehicle reaches the gear-shifting inputted rotational speed, controlling a shifting fork to start up a gear-shifting operation (103). The method for controlling gear shifting presets the target rotational speed of the gears, and, according to the current gear-shifting parameter of the vehicle that is acquired in real time and the preset target rotational speed, inversely calculates the gear-shifting inputted rotational speed, whereby the gear-shifting inputted rotational speed is an accurate gear-shifting inputted rotational speed that matches with the current condition of the vehicle.

Abstract: The embodiments disclosed herein provide compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, wherein R1 to R7 are as defined in the description. This application also provides a preparation method and a medical use of the compounds. The compounds of this disclosure have an activity superior or equivalent to the candidate drug LY2835219 currently under phase III clinical trial, and some of the compounds exhibit better selectivity. Moreover, the preferred compounds exhibit good absorption and good blood-brain distribution when administered orally.

Abstract: A method for controlling gear shifting, including: acquiring a current gear-shifting parameter of the vehicle (101); according to the current gear-shifting parameter and a preset target rotational speed, determining a gear-shifting inputted rotational speed (102); and when a rotational speed of the vehicle reaches the gear-shifting inputted rotational speed, controlling a shifting fork to start up a gear-shifting operation (103). The method for controlling gear shifting presets the target rotational speed of the gears, and, according to the current gear-shifting parameter of the vehicle that is acquired in real time and the preset target rotational speed, inversely calculates the gear-shifting inputted rotational speed, whereby the gear-shifting inputted rotational speed is an accurate gear-shifting inputted rotational speed that matches with the current condition of the vehicle.

Abstract: A method and apparatus for correcting a physical slip and wear coefficient of a clutch comprising obtaining a torque difference according to a positional relation between an engine and the clutch; obtaining a correction weight value corresponding to an engine torque according to the torque difference; and correcting the physical slip and wear coefficient according to the correction weight value and a running-in state of the clutch. The method relates to obtaining a torque difference in real time by means of a positional relation between the engine and the clutch in a manner corresponding to the positional relation, obtaining a correction weight value corresponding to the engine torque according to the torque difference, and further correcting the physical slip and wear coefficient by combining the correction weight value and a running-in state of the clutch.

Abstract: A method and apparatus for correcting a physical slip and wear coefficient of a clutch comprising obtaining a torque difference according to a positional relation between an engine and the clutch; obtaining a correction weight value corresponding to an engine torque according to the torque difference; and correcting the physical slip and wear coefficient according to the correction weight value and a running-in state of the clutch. The method relates to obtaining a torque difference in real time by means of a positional relation between the engine and the clutch in a manner corresponding to the positional relation, obtaining a correction weight value corresponding to the engine torque according to the torque difference, and further correcting the physical slip and wear coefficient by combining the correction weight value and a running-in state of the clutch.

Abstract: The invention provides a compound of Formula I, or its tautomer, mesomer, racemate, enantiomer, diastereoisomer or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compound of Formula I, its tautomer, mesomer, racemate, enantiomer, or diastereoisomer. Ring A, R1, R2, R3 and R4 are as defined in the specification. The invention further provides a method for preparing the compound of Formula I and their use in the manufacture of a medicament for the treatment of a cell proliferative disorder.

Abstract: The embodiments disclosed herein provide compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, wherein R1 to R7 are as defined in the description. This application also provides a preparation method and a medical use of the compounds. The compounds of this disclosure have an activity superior or equivalent to the candidate drug LY2835219 currently under phase III clinical trial, and some of the compounds exhibit better selectivity. Moreover, the preferred compounds exhibit good absorption and good blood-brain distribution when administered orally.

Abstract: The invention provides a compound of Formula I, or its tautomer, mesomer, racemate, enantiomer, diastereoisomer or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compound of Formula I, its tautomer, mesomer, racemate, enantiomer, or diastereoisomer. Ring A, R1, R2, R3 and R4 are as defined in the specification. The invention further provides a method for preparing the compound of Formula I and their use in the manufacture of a medicament for the treatment of a cell proliferative disorder.

Abstract: The method for preparing fluorine-doped lamellar black TiO2 nanomaterials includes mixing a solution of tetra-n-butyl titanate, n-propanol and hydrofluoric acid together, and then stir the solutions for a period of time. The solution is transferred into an autoclave and reacts at a certain temperature for a period of time. The sample obtained by the reaction is washed and dried. Then, the sample is heated in a protective atmosphere for a period of time so as to produce the fluorine-doped lamellar black TiO2 nanomaterials. This fluorine-doped lamellar black TiO2 owns superior optical absorption and electron transport performances.

Abstract: The method for preparing fluorine-doped lamellar black TiO2 nanomaterials includes mixing a solution of tetra-n-butyl titanate, n-propanol and hydrofluoric acid together, and then stir the solutions for a period of time. The solution is transferred into an autoclave and reacts at a certain temperature for a period of time. The sample obtained by the reaction is washed and dried. Then, the sample is heated in a protective atmosphere for a period of time so as to produce the fluorine-doped lamellar black TiO2 nanomaterials. This fluorine-doped lamellar black TiO2 owns superior optical absorption and electron transport performances.

Abstract: A lead-free free-cutting corrosion-resistant silicon-bismuth brass alloy, including the following: between 60.0 and 65.0 wt % of Cu, between 0.6 and 1.8 wt % of Si, between 0.2 and 1.5 wt % of Bi, between 0.02 and 0.5 wt % of Al, less than 1.5 wt % of Ni+Mn+Sn, between 0.01 and 0.5 wt % of La—Ce alloy, between 0.002 and 0.02 wt % of B, with the remainder being Zn and inevitable impurities, wherein the total amount of impurities are no more than 0.5 wt %.

Abstract: Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of the compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

Abstract: A lead-free free-cutting corrosion-resistant silicon-bismuth brass alloy, including the following: between 60.0 and 65.0 wt % of Cu, between 0.6 and 1.8 wt % of Si, between 0.2 and 1.5 wt % of Bi, between 0.02 and 0.5 wt % of Al, less than 1.5 wt % of Ni+Mn+Sn, between 0.01 and 0.5 wt % of La—Ce alloy, between 0.002 and 0.02 wt % of B, with the remainder being Zn and inevitable impurities, wherein the total amount of impurities are no more than 0.5 wt %.

Abstract: Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.